Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease.
- Author:
Belen LOPEZ-MILLAN
1
;
Rafael DIAZ DE LA GUARDIA
;
Heleia ROCA-HO
;
Carmen M GARCÍA-HERRERO
;
Jessie R LAVOIE
;
Michael ROSU-MYLES
;
Elena GONZALEZ-REY
;
Francisco O'VALLE
;
Gabriel CRIADO
;
Mario DELGADO
;
Pablo MENENDEZ
Author Information
- Publication Type:Original Article
- MeSH: Arthritis, Experimental; Arthritis, Rheumatoid*; Cytokines; Dextran Sulfate; Humans; In Vitro Techniques; Inflammatory Bowel Diseases*; Lymphocytes; Models, Theoretical*; Thalidomide; Therapeutic Uses
- From:Experimental & Molecular Medicine 2017;49(2):e290-
- CountryRepublic of Korea
- Language:English
- Abstract: Thalidomide is an immunomodulatory drug (IMiD) with proven therapeutic action in several autoimmune/inflammatory diseases; however, its inherent high toxicity has led to the development of more powerful and safer thalidomide analogs, including lenalidomide and pomalidomide. These are new generation IMiDs that exhibit direct antitumor activity as well as anti-inflammatory/immunomodulatory properties, and are FDA-approved for the treatment of several hematological malignances. Here we investigated the potential therapeutic effects of lenalidomide and pomalidomide in several experimental murine models of autoimmune/inflammatory diseases: 2,4,6-trinitrobenzene sulfonic acid- and dextran sulfate sodium-induced inflammatory bowel disease and type II collagen-induced arthritis. Lenalidomide displayed a strong therapeutic effect in all these models of autoimmune/inflammatory diseases, while the effect of pomalidomide was less pronounced. In vitro experiments confirmed the immunosuppressive effect of both IMiDs on the proliferative response of stimulated human lymphocytes and on the balance of secreted cytokines toward an anti-inflammatory profile. We conclude that lenalidomide may offer a therapeutic opportunity against autoimmune/inflammatory diseases.
